• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

淋巴浆细胞淋巴瘤中溶骨性骨病的管理：一例报告并文献复习

Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.

作者信息

Baksh Mizba, Jiang Liuyan, Bhatia Unnati, Alegria Victoria, Sher Taimur, Roy Vivek, Chanan-Khan Asher, Ailawadhi Sikander, Parrondo Ricardo D

机构信息

Division of Hematology-Oncology Mayo Clinic Jacksonville Florida USA.

Department of Pathology Mayo Clinic Jacksonville Florida USA.

出版信息

Clin Case Rep. 2021 Dec 7;9(12):e05181. doi: 10.1002/ccr3.5181. eCollection 2021 Dec.

DOI:10.1002/ccr3.5181
PMID:34934497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8650751/
Abstract

Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood. We describe a case of an 81-year-old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.

摘要

华氏巨球蛋白血症（WM）/淋巴浆细胞淋巴瘤（LPL）通常根据溶骨性骨病变（LBL）的存在与骨髓瘤相鉴别。然而，WM/LPL也可出现LBL，且对其治疗方法了解甚少。我们描述了一例81岁患有LPL的女性患者，该患者出现了LBL，并通过化疗免疫疗法成功治愈。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45ac/8650751/44b367099e8d/CCR3-9-e05181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45ac/8650751/3448fb1ee398/CCR3-9-e05181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45ac/8650751/44b367099e8d/CCR3-9-e05181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45ac/8650751/3448fb1ee398/CCR3-9-e05181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45ac/8650751/44b367099e8d/CCR3-9-e05181-g003.jpg

相似文献

1
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.淋巴浆细胞淋巴瘤中溶骨性骨病的管理：一例报告并文献复习
Clin Case Rep. 2021 Dec 7;9(12):e05181. doi: 10.1002/ccr3.5181. eCollection 2021 Dec.
2
Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.华氏巨球蛋白血症和非 IgM 型淋巴浆细胞淋巴瘤在遗传学上相似。
Acta Haematol. 2023;146(5):384-390. doi: 10.1159/000530100. Epub 2023 Mar 14.
3
Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.淋巴浆细胞淋巴瘤/华氏巨球蛋白血症伴实体瘤和髓系恶性肿瘤的家族聚集性。
Acta Haematol. 2012;127(3):173-7. doi: 10.1159/000335618. Epub 2012 Feb 3.
4
Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.累及髓外部位的华氏巨球蛋白血症：44例患者的形态学和免疫表型研究结果
Am J Surg Pathol. 2003 Aug;27(8):1104-13. doi: 10.1097/00000478-200308000-00007.
5
Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.仅表达λ轻链单克隆副蛋白的淋巴浆细胞淋巴瘤
Eur J Case Rep Intern Med. 2022 Feb 11;9(2):003106. doi: 10.12890/2022_003106. eCollection 2022.
6
Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.淋巴浆细胞淋巴瘤和华氏巨球蛋白血症。
Arch Pathol Lab Med. 2013 Apr;137(4):580-5. doi: 10.5858/arpa.2012-0034-RS.
7
Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.淋巴浆细胞淋巴瘤和华氏巨球蛋白血症：临床病理特征和鉴别诊断。
Pathology. 2020 Jan;52(1):6-14. doi: 10.1016/j.pathol.2019.09.009. Epub 2019 Nov 22.
8
Biclonal lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with POEMS syndrome: A case report and literature review.双克隆淋巴浆细胞淋巴瘤/华氏巨球蛋白血症合并POEMS综合征：一例报告及文献复习
Oncol Lett. 2023 Jan 27;25(3):97. doi: 10.3892/ol.2023.13683. eCollection 2023 Mar.
9
Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.非华氏巨球蛋白血症型淋巴浆细胞淋巴瘤的临床特征与转归：一项瑞典淋巴瘤登记研究
Br J Haematol. 2022 Mar;196(6):1362-1368. doi: 10.1111/bjh.18002. Epub 2021 Dec 27.
10
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.淋巴浆细胞淋巴瘤/华氏巨球蛋白血症中的核蛋白失调。
Am J Clin Pathol. 2013 Feb;139(2):210-9. doi: 10.1309/AJCP0YGM8BLFYHJY.

引用本文的文献

1
Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study.骨受累作为华氏巨球蛋白血症的一种原发性罕见表现：一例报告及全国基于人群队列研究中的患病率
J Hematol. 2022 Dec;11(6):233-239. doi: 10.14740/jh1073. Epub 2022 Dec 30.

本文引用的文献

1
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.多发性骨髓瘤相关骨病的治疗：国际骨髓瘤工作组骨工作组的建议。
Lancet Oncol. 2021 Mar;22(3):e119-e130. doi: 10.1016/S1470-2045(20)30559-3. Epub 2021 Feb 2.
2
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.第十届瓦尔登斯特伦巨球蛋白血症国际研讨会的共识治疗建议。
Lancet Haematol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6.
3
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
伊布替尼单药治疗有症状、既往治疗的华氏巨球蛋白血症患者的长期随访。
J Clin Oncol. 2021 Feb 20;39(6):565-575. doi: 10.1200/JCO.20.00555. Epub 2020 Sep 15.
4
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.免疫球蛋白 M（IgM）多发性骨髓瘤与华氏巨球蛋白血症：诊断挑战与治疗选择：两例报告。
J Med Case Rep. 2020 Jun 22;14(1):75. doi: 10.1186/s13256-020-02380-2.
5
Mixed Lytic and Blastic Bone Lesions as a Presenting Feature of Waldenström Macroglobulinemia: Case Report and Review of the Literature.混合性溶骨性和成骨性骨病变作为华氏巨球蛋白血症的首发特征：病例报告及文献复习
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e87-e91. doi: 10.1016/j.clml.2019.11.009. Epub 2019 Nov 21.
6
What is new in the treatment of Waldenstrom macroglobulinemia?瓦尔登斯特伦巨球蛋白血症的治疗有哪些新进展？
Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7.
7
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.苯达莫司汀和利妥昔单抗（BR）对比地塞米松、利妥昔单抗和环磷酰胺（DRC）在华氏巨球蛋白血症患者中的疗效。
Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3.
8
Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.IgM 型多发性骨髓瘤病例报告：诊断一种罕见的血液学实体。
Cancer Control. 2018 Jan-Mar;25(1):1073274817744448. doi: 10.1177/1073274817744448.
9
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.CD38在骨髓瘤骨龛中的表达：使用抗CD38免疫疗法抑制破骨细胞形成的合理依据。
Oncotarget. 2017 May 16;8(34):56598-56611. doi: 10.18632/oncotarget.17896. eCollection 2017 Aug 22.
10
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.伊布替尼治疗利妥昔单抗难治性华氏巨球蛋白血症患者（iNNOVATE）：一项国际多中心 3 期临床试验的开放性亚研究。
Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.